Acurx Pharmaceuticals, Inc. (ACXP)
NASDAQ: ACXP · Real-Time Price · USD
1.660
-0.190 (-10.27%)
At close: Feb 20, 2026, 4:00 PM EST
1.770
+0.110 (6.63%)
After-hours: Feb 20, 2026, 7:42 PM EST
Acurx Pharmaceuticals Employees
Acurx Pharmaceuticals had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,292,513
Market Cap
4.23M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2023 | 4 | 0 | - | 4 | 0 |
| Dec 31, 2022 | 4 | 1 | 33.33% | 4 | 0 |
| Sep 30, 2022 | 4 | 1 | 33.33% | 4 | 0 |
| Dec 31, 2021 | 3 | 0 | - | 3 | 0 |
| Mar 31, 2021 | 3 | - | - | 2 | 1 |
| Dec 31, 2020 | 3 | - | - | 2 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| VivoSim Labs | 14 |
| Genprex | 13 |
| Processa Pharmaceuticals | 10 |
| MetaVia | 9 |
| Dermata Therapeutics | 8 |
| PMGC Holdings | 3 |
| Decoy Therapeutics | 2 |
| Xenetic Biosciences | 2 |
ACXP News
- 5 days ago - Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update - PRNewsWire
- 19 days ago - USPTO Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors - PRNewsWire
- 3 months ago - Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals - PRNewsWire
- 3 months ago - Acurx Pharmaceuticals, Inc. (ACXP) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Acurx Pharmaceuticals, Inc. Reports Third Quarter Results and Provides Business Update - PRNewsWire
- 3 months ago - Acurx Announces Publication in the Nature Communications Scientific Journal Documenting its Unique Targeting of DNA pol IIIC Gram-positive Priority Pathogens - PRNewsWire
- 4 months ago - Acurx Announces New Data on its DNA pol IIIC Inhibitor Antibiotics Demonstrating a Potential Class Effect of Gut Microbiome Selectivity Presented at IDWeek 2025 Scientific Conference - PRNewsWire
- 4 months ago - Acurx Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 12, 2025 Conference Call and Provide Business Update - PRNewsWire